Sonnet Biotherapeutics Company Leadership
| SONN Stock | USD 2.90 0.02 0.68% |
Sonnet Biotherapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Sonnet Biotherapeutics Holdings suggests that virtually all insiders are extremely bullish. Sonnet Biotherapeutics employs about 12 people. The company is managed by 8 executives with a total tenure of roughly 28 years, averaging almost 3.0 years of service per executive, having 1.5 employees per reported executive.
Sonnet Biotherapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-06-14 | Susan Dexter | Acquired 454 @ 15.4 | View | ||
| 2023-05-30 | Albert D Dyrness | Acquired 1057 @ 10.34 | View | ||
| 2023-05-17 | Nailesh Bhatt | Acquired 1136 @ 5.06 | View | ||
| 2023-05-15 | Pankaj Mohan | Acquired 16890 @ 4.84 | View |
Monitoring Sonnet Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Sonnet |
Sonnet Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sonnet Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Sonnet will maintain a workforce of about 12 employees by December 2024.Sonnet Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9693) % which means that it has lost $0.9693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6457) %, meaning that it created substantial loss on money invested by shareholders. Sonnet Biotherapeutics' management efficiency ratios could be used to measure how well Sonnet Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -1.72. In addition to that, Return On Capital Employed is likely to grow to -0.17. At this time, Sonnet Biotherapeutics' Other Assets are very stable compared to the past year. As of the 22nd of November 2024, Net Tangible Assets is likely to grow to about 9 M, while Total Assets are likely to drop about 28.3 M.As of the 22nd of November 2024, Common Stock Shares Outstanding is likely to drop to 417.60. In addition to that, Net Loss is likely to drop to about (16.9 M)
Sonnet Biotherapeutics Workforce Comparison
Sonnet Biotherapeutics Holdings is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 870. Sonnet Biotherapeutics claims roughly 12.0 in number of employees contributing just under 2% to equities under Health Care industry.
Sonnet Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonnet Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonnet Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sonnet Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-03-01 | 0.8333 | 5 | 6 | 181,366 | 123,823 |
| 2021-06-01 | 1.3333 | 4 | 3 | 57,000 | 28,384 |
| 2019-12-01 | 5.0 | 5 | 1 | 3,365 | 400,000 |
| 2019-06-01 | 7.6667 | 23 | 3 | 209,481 | 14,500 |
| 2018-12-01 | 4.6667 | 14 | 3 | 24,706 | 50,000 |
| 2018-06-01 | 0.4444 | 8 | 18 | 133,200 | 17,000 |
| 2018-03-01 | 0.75 | 3 | 4 | 16,757 | 12,834 |
| 2017-12-01 | 2.5 | 5 | 2 | 9,315 | 2,300,000 |
| 2017-09-01 | 4.0 | 4 | 1 | 847.00 | 0.00 |
| 2017-06-01 | 9.0 | 9 | 1 | 11,432 | 5,000 |
| 2017-03-01 | 3.0 | 3 | 1 | 8,300 | 0.00 |
| 2016-09-01 | 10.0 | 10 | 1 | 17,200 | 0.00 |
| 2014-12-01 | 6.0 | 6 | 1 | 59,886 | 44,000 |
| 2014-06-01 | 1.0 | 1 | 1 | 300.00 | 0.00 |
| 2013-12-01 | 2.0 | 2 | 1 | 8,376 | 0.00 |
| 2013-03-01 | 2.0 | 2 | 1 | 1,400 | 0.00 |
| 2012-09-01 | 2.0 | 2 | 1 | 1,000.00 | 0.00 |
| 2010-03-01 | 4.0 | 4 | 1 | 1,350 | 133,164 |
| 2007-12-01 | 0.5 | 1 | 2 | 625,000 | 625,000 |
| 2007-09-01 | 1.0 | 1 | 1 | 150.00 | 2,500 |
| 2006-09-01 | 2.0 | 2 | 1 | 2,500 | 1,200 |
Sonnet Biotherapeutics Notable Stakeholders
A Sonnet Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sonnet Biotherapeutics often face trade-offs trying to please all of them. Sonnet Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sonnet Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pankaj Mohan | Chairman, Founder | Profile | |
| CPA CPA | Controller Director | Profile | |
| Manuel Dafonseca | Head Operations | Profile | |
| Gael Hedou | Chief Officer | Profile | |
| John Cini | Chief CoFounder | Profile | |
| MD FACP | Chief Officer | Profile | |
| Jay Cross | Chief Officer | Profile | |
| Susan Dexter | Chief Officer | Profile |
About Sonnet Biotherapeutics Management Performance
The success or failure of an entity such as Sonnet Biotherapeutics often depends on how effective the management is. Sonnet Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sonnet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sonnet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.63) | (1.72) | |
| Return On Capital Employed | (0.18) | (0.17) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.92) | (0.88) |
Sonnet Biotherapeutics Workforce Analysis
Traditionally, organizations such as Sonnet Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sonnet Biotherapeutics within its industry.Sonnet Biotherapeutics Manpower Efficiency
Return on Sonnet Biotherapeutics Manpower
| Revenue Per Employee | 12.3K | |
| Revenue Per Executive | 18.5K | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 2.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.